CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis.

CD133 is a transmembrane protein that is proposed to be a stem cell marker of colorectal cancer (CRC); however, the correlation between CD133 expressi...
18KB Sizes 0 Downloads 9 Views
Download PDF

Recommend Documents

Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome.
Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery.
Young patients with synchronous colorectal liver metastases.
Recurrence pattern depends on the location of colon cancer in the patients with synchronous colorectal liver metastasis.
EMX2 gene expression predicts liver metastasis and survival in colorectal cancer.
Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Metastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma.
CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer.

Follow Us

Copyright © 2024 D.DOCKSCI.COM. All rights reserved. | Design by w3layouts